Kids V Cancer named one of top 10 most innovative companies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

KIDS V CANCER was named as one of Fast Company’s Top 10 Most Innovative Companies of 2016 in Not-For-Profit, placing fourth. Fast Company praised Kids v Cancer for accelerating the discovery of pediatric cancer treatments.

Other organizations in this category include Black Lives Matter, 92nd St Y, Humans Of New York and UNICEF. Last year, Kids v Cancer received the 2015 Peter F. Drucker Award for Nonprofit Innovation.

Through the Creating Hope Act, Kids v Cancer has mobilized almost $1 billion for research and development of drugs. With the valuation of a Creating Hope Act pediatric priority review voucher reaching $350 million, biotech and pharmaceutical companies are now focusing on business plans built around pediatric rare disease drug development.

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login